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Abstract 
One in ten patients suffering from primary spontaneous pneumothoraces has a 
family history of the disorder.  Such familial pneumothoraces can occur in isolation, 
but can also be the presentation of serious genetic disorders with life-threatening 
vascular or cancerous complications.  As the pneumothorax frequently precedes 
the more dangerous complications by many years, it provides an opportunity to 
intervene in a focused manner, permitting the practice of precision medicine.  In 
this review, we will discuss the clinical manifestations and underlying biology of the 




In elephants, fusion of the visceral and parietal pleura fixes the lung to the chest 
wall (1).  This developmental pleurodesis may have evolved to prevent 
pneumothoraces caused by the high transmural pressures experienced during 
trunk-snorkelling (1).  Humans, by contrast, do not share this adaptation and so a 
potential pleural space persists that can fill with air if the lung or chest wall are 
punctured.  A spontaneous pneumothorax occurs when air enters the pleural 
space in the absence of trauma.  Owing to positive transmural pressure across the 
visceral pleura, this deflates the lung to a degree dependant upon how efficiently 
the puncture closes (2).  Many spontaneous pneumothoraces occur secondarily to 
lung pathology, in particular chronic obstructive pulmonary disease (COPD), but 
those occurring in apparently healthy individuals are labelled ‘primary spontaneous 
pneumothoraces’.   
Classically, primary spontaneous pneumothoraces present in patients between the 
ages of 18 to 40, and are four-fold more common in males, with an annual 
incidence of 4–18 per 100,000 in men and 1.2–6 per 100 000 in women (3).  
Affected individuals are often tall and thin, perhaps reflecting the higher transmural 
pressures experienced at the apices of elongated lungs, although it is equally 
possible that taller individuals have connective tissues of lower tensile strengths.  
The pathogenic mechanisms of primary spontaneous pneumothorax remain 
incompletely understood, but thoracic computed tomography (CT) identifies 
ipsilateral apical sub-pleural blebs or bullae in 89% of patients with primary 
spontaneous pneumothorax compared to 20% of controls (4).  Likewise, at 
surgery, between 76-100% are found to have blebs or bullae, although this may be 
biased towards more severe cases (2, 5).  
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A family history of pneumothorax can be elicited in 10% of individuals presenting 
with spontaneous pneumothorax (6).  Indeed, the term familial spontaneous 
pneumothorax was first coined a century ago in the report of an affected pair of 
identical twins (7).  The diagnosis of familial cases is important not only to optimise 
current management, but also to allow more serious complications of the causative 
mutation to be anticipated and treated (Figure 1).  It is therefore important to 
recognise these cases and elucidate the molecular defect causing a familial 
pneumothorax, enabling proactive, individualised care – a true application of so-
called ‘precision medicine’. 
Inherited connective tissue disorders account for a proportion of such cases.  A 
second group of familial pneumothoraces is defined by mutations that affect 
tumour suppressor pathways (8-10).  These mutations frequently lead to the 
formation of pulmonary cysts that rupture to cause pneumothorax.  Again, early 
diagnosis is essential to put in place the necessary surveillance and management 
of life-threatening extra-thoracic complications (11).  The health benefits can be 
extended by identifying relatives who share the mutation and are also at risk of 
disease.  A proportion of individuals with familial pneumothorax currently fails to be 
given a genetic diagnosis, but the advent of inexpensive genome sequencing 
offers an opportunity to define the genetic landscape of familial pneumothorax.  
 
Defects of tumour suppressors 
A group of disorders that can present as familial pneumothorax involves mutations 
in tumor suppressor genes.  Two classic examples are Birt-Hogg-Dube syndrome 
and tuberous sclerosis complex (TSC), both of which have been linked to the 
kinase mechanistic target of rapamycin (mTOR), a master regulator of protein 
synthesis that links environmental cues with cell growth and proliferation (12).  
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Activation of mTOR complex 1 (mTORC1) enhances protein translation, inhibits 
autophagy, and initiates a series of metabolic adaptations to promote cell growth, 
including increases in nucleotide biosynthesis.  mTORC1 is tonically inhibited by 
hamartin (TSC1), tuberin (TSC2), and TBC1D7 (13).  In turn, inhibition of these 
TSC regulators by growth signals or mutations can activate (or disinhibit) the 
mTOR pathway, leading to complex multi-system phenotypes in patients with TSC 
(discussed below) and to sporadic human malignancies, renal cystic disease, and 
many other disorders.  
 
Birt-Hogg-Dubé syndrome 
Birt-Hogg-Dubé syndrome (BHD) is the most common genetic cause of familial 
pneumothorax, accounting for 10-15% of all cases (14, 15).  It is an autosomal 
dominant condition caused by inactivating mutations in the FLCN gene that 
encodes the folliculin protein (16-18).  Patients with BHD can develop pulmonary 
cysts, facial fibrofolliculomas, renal cell carcinoma and renal oncocytoma.  Loss of 
folliculin leads enhances cell proliferation (19), but the mechanisms of this are 
unclear.  Folliculin has a complex connection to the mTOR pathway.  In mice, 
inactivating Flcn mutations have been found to both enhance and inhibit mTORC1 
activity (20-22).  In cells, folliculin is required for activation of mTORC1 at the 
lysosome, with folliculin-deficient cells showing decreased mTORC1 activity (23, 
24).   
Diagnosis of Birt-Hogg-Dubé syndrome can be challenging.  Fibrofolliculomas are 
the most common skin lesion in this syndrome and appear as small dome-shaped 
papules on the face, neck and upper trunk from the third decade onwards.  These 
skin lesions can aid in diagnosis, but the dermatological features are absent in a 
quarter of adults with FLCN mutations and so the disorder can often present 
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instead with pneumothorax or renal cancer (25).  Renal malignancies occur later in 
life and are curable surgically if identified when still small (26).  For this reason, a 
diagnosis of BHD following a pneumothorax provides individuals and their affected 
relatives with the benefits of annual surveillance imaging, ideally with renal MRI 
scanning, to identify early renal tumours when they can be easily treated. 
Lung cysts and spontaneous pneumothorax are common features of BHD  (Figure 
2).  Histologically, cysts are lined with epithelium and can have internal septations 
but the parenchyma between them is usually normal (27, 28).  Up to 86% of 
patients with FLCN mutations have lung cysts, which on thoracic CT imaging have 
a characteristic predominantly basal distribution and irregular shape (29, 30).  
Forty per cent of cysts abut the pleura, which likely explains why patients with BHD 
have a 24-48% lifetime risk of pneumothorax (31, 32).  In contrast to the general 
population, individuals with FLCN mutations do not show an obvious difference in 
the incidence of pneumothorax between the sexes nor is there a detectable 
interaction with smoking (32).  In this condition, spontaneous pneumothorax is 
most likely to develop in the fourth and fifth decade — the median age of first 
pneumothorax being 38 years.  The presence and size of cysts both correlate 
significantly with the likelihood of developing pneumothorax (16).   
Remarkably, although the clinical evidence points towards a causal relationship 
between cyst formation and the development of pneumothorax, the mechanistic 
link between FLCN mutation and cyst development is not known.  In a series of 
patients with heterozygous FLCN mutations, cyst tissue consistently stained 
positively for phosphorylate S6 ribosomal protein, a classical mTORC1 target, 
suggesting activation of mTOR (27).  This led to a suggestion that cysts might 
represent hamartomatous alveolus formation.  Indeed, human alveolar cells from 
patients with FLCN mutations show evidence of mTORC1 activation (33).  
 7 
However, folliculin can also bind to plakophilin-4, a protein involved in the 
formation of adherens junctions (34, 35), and cell-cell adhesion is enhanced when 
cells lack either folliculin or plakophilin-4 (33, 35, 36).  This led to the proposal of a 
‘stretch hypothesis’ in which enhanced cell-cell adhesion results from reduced 
formation of the folliculin-plakophilin-4 complex (36).  Consequently, reduced 
expression of folliculin would diminish the compliance of lung parenchyma 
rendering it more susceptible to alveolar rupture during cycles of inspiration and 
expiration (35-37).  Since most tidal respiration occurs in the lower zones of the 
lung, the stretch hypothesis offers an appealing mechanism to explain the 
distribution of lung cysts in BHD.  Nevertheless, the mTOR and stretch hypotheses 
are not mutually exclusive. 
Determining the true nature of the disease mechanism(s) is more than an 
academic concern.  It is necessary to enable the development of rational therapies.  
At present, apart from surveillance for renal tumours, specific therapies for BHD 
are lacking.  Antagonism of mTOR has been proposed as a potential strategy 
because in Flcn knockout mice rapamycin has been shown to reduce the 
development of renal cysts and extend survival (22, 38).  However, given the 
uncertainty (discussed above) about whether folliculin is an activator or an inhibitor 
of mTORC1, and the uncertainty about whether renal cysts in the Flcn knockout 
mice are an appropriate surrogate for pneumothorax and/or renal cell carcinoma in 
patients with BHD, it will be important to determine the impact of mTORC1 
inhibition in the human disease.  Currently, a Phase II trial of everolimus, an 
mTORC1 allosteric inhibitor, is ongoing for BHD syndrome-associated renal cancer 
(NCT02504892).  
From a clinical perspective, establishing a correct diagnosis of BHD enables early 
detection of renal cell carcinomas in both the proband and in undiagnosed family 
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members who also carry the FLCN mutation.  All BHD patients should have regular 
renal imaging, typically every two years if no tumours are detected or more often to 
monitor the growth of small tumours.   
Tuberous Sclerosis and lymphangioleiomyomatosis 
Tuberous sclerosis complex (TSC) is caused by inactivating mutations in the TSC1 
and TSC2 genes (39). These encode tumour suppressors and so loss of 
heterozygosity or inactivation of the wild-type allele, which almost always occurs 
via somatic mutational events, can lead to hamartoma development in a variety of 
organs, typically the brain, kidney, skin, retina and lung (40).  The relevance of 
tuberous sclerosis to pneumothorax stems from its strong association with 
lymphangioleiomyomatosis (LAM).  Sporadic LAM is rare, affecting only 1 in 
1,000,000 women of childbearing age, and appears to be caused in most cases by 
somatic mutations in the TSC2 gene (41, 42).  By contrast, tuberous sclerosis 
occurs in 1 in 5000-10,000 births (43) and CT screening studies suggests that 34-
80% of women with TSC mutations (and 0-10% of men) have pulmonary cysts 
consistent with LAM (44-46).   
The female preponderance of LAM is hypothesised to reflect a sensitivity to female 
sex hormones since disease progression can accelerate dramatically during 
pregnancy and the disease progresses more rapidly during the premenopausal 
years.  Both LAM and angiomyolipoma cells stain positively for oestrogen and/or 
progesterone receptors (47).  The nature of the germline TSC mutation does not 
appear to influence the risk of developing LAM, although in general patients with 
TSC1 mutations develop disease of lesser severity when compared with patients 
with TSC2 mutations (48).  LAM carries a 60–81% lifetime risk of pneumothorax 
and recurrence rates are more than 70% (9, 10).  Unlike Birt-Hogg-Dubé, the thin-
walled pulmonary cysts in LAM distribute evenly throughout all regions of the lung 
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(49-51)(Figure 3).  Histologically LAM is characterised by an abnormal proliferation 
of smooth muscle-like cells in the alveolar septa that cause progressive cystic lung 
destruction. So-called ‘LAM cells’ characteristically stain with antibody HMB-45, 
which recognises gp100 a melanocyte marker, leading some to suggest they arise 
from a melanocyte and/or neural crest-lineage precursor (52). 
Some patients with LAM suffer progressive loss of lung function that can eventually 
necessitate lung transplantation.  Circulating VEGF-D is a validated diagnostic 
biomarker of LAM and may also have utility in predicting the likelihood of disease 
progression (53).  Importantly, in those patients with progressive loss of lung 
function, inhibition of mTORC1 has proven successful in delaying the progression 
of cystic lung disease and preserving lung function, although the loss of lung 
function recurs when the drug is stopped so lifelong therapy appears to be 
necessary (11, 54).   
Distinguishing between TSC-LAM (with germline TSC1 or TSC2 gene mutations) 
and sporadic LAM can be challenging.  All women with LAM should be screened 
for renal angiomyolipomas, which occur in both TSC-LAM and sporadic LAM and 
can spontaneously hemorrhage.  Women with apparently sporadic LAM who are 
considering having children should be carefully screened for clinical evidence of 
TSC (imaging of the brain, MRI or CT imaging of the kidneys, and formal 
dermatologic exam for manifestations of TSC) because of the autosomal dominant 
transmission of germline TSC gene mutations.  Some women with apparently 
sporadic LAM who lack germline TSC gene mutations may have a somatic mosaic 
form of TSC.  Additional considerations for women with LAM considering 
pregnancy, related to the possible effects of pregnancy-related hormonal changes 
on the progression of LAM, should be handled in an individualized basis.   
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True connective tissue disorders 
The biomechanical properties that determine a tissue’s propensity for spontaneous 
rupture are dependent on the extra-cellular matrix secreted by component cells.  
Mutations that affect the mechanical properties of matrix proteins, such as those 
implicated in the connective tissue disorders, therefore have direct effects on the 
tensile strength and behaviour of many tissues.  This is particularly important to 
hollow viscera that experience significant positive transmural pressures, such as 
blood vessels and the lungs.  Consequently, the same mutation that causes the 
visceral pleura to fail, causing a pneumothorax, can sometimes cause life-
threatening arterial rupture.  Identification of those patients at risk of vascular 
catastrophe enables pre-emptive pharmacological treatment, monitoring and, when 
required, surgical reinforcement or replacement of affected vessels.  In this 
context, even a small, non-threatening pneumothorax represents a sentinel event, 
serving as a harbinger for potentially lethal vascular complications.   
Marfan syndrome 
Spontaneous pneumothorax occurs in 4.4–10.5% of individuals with Marfan 
syndrome, which represents a 1000-fold excess compared to the general 
population (55).  Indeed, pneumothorax is one of the phenotypes that contributes 
to the systemic scores used to evaluate patients with the syndrome (see 
https://www.marfan.org/dx/score).  Marfan syndrome is transmitted in an 
autosomal dominant manner due to mutation of the FBN1 gene.  FBN1 is highly 
polymorphic and prone to mutation.  As a result, 25% of cases result from de novo 
mutations (56), and thus can present in the absence of a family history.  FBN1 
encodes a glycoprotein, fibrillin-1, that forms microfibrils closely associated with 
elastin fibres in tendons, skin, cartilage, periosteum and the cardiovascular system.  
Pathogenic mutations therefore have widespread manifestations.  Abnormal bone 
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growth leads to tall stature, disproportionately long limbs and digits 
(arachnodactyly), scoliosis, pectus excavatum or carinatum, and pes planus; whilst 
dysfunction of the suspensory ligaments of the lens can cause subluxation of the 
lens.  In the cardiovascular system, aortic dilatation, particularly of the root, is 
widely recognised.  Other cardiac features include for example valve prolapse, 
most commonly of the mitral valve with associated regurgitation, enlargement of 
the proximal pulmonary artery and cardiomyopathy. 
The mechanism of pneumothorax in Marfan syndrome might be explained either 
as a consequence of the physiological impact of the body habitus of affected 
individuals, through increased focal parenchymal tension by musculoskeletal 
deformity, faulty connective tissue integrity from lack of fibrillin or altered elastin, or 
through biochemical effects via aberrant transforming growth factor β (TGFβ) 
signaling.  As mentioned above, elongation of the thorax can lead to increased 
apical transmural pressures across the visceral pleura and so contribute to bleb 
formation.  The frequency of blebs in patients with Marfan syndrome is 5–9.6% 
(55) and those who develop blebs are 10-fold more likely to develop pneumothorax 
than those without, 25% vs 2.7% (55).  However, in many patients with Marfan 
syndrome, the extreme height is due to increased extremity length without an 
increase in torso height.  Frequently, patients have significant musculoskeletal 
deformity, including kyphoscoliosis or pectus deformities.  These are occasionally 
severe and could contribute to local parenchymal tension (57, 58). 
In addition to its structure functions, fibrillin-1 also has a role in regulating 
transforming growth factor β (TGFβ) signalling, which may be relevant to the 
pathology of Marfan syndrome.  Mice deficient in Fbn1 have abnormally elevated 
TGFβ signalling with accompanying distal airspace enlargement and aortic 
dilatation, which are antecedents of spontaneous pneumothorax and aortic rupture 
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(59, 60).  Mechanistic support for the importance of this function on fibrillin-1 
comes from experiments in which administration of TGFβ-neutralizing antibody 
attenuated these manifestations.  Angiotensin receptor blockade can also 
antagonise TGFβ signalling, which may account for the protection afforded by 
losartan, but not β-adrenergic receptor blockade, against aortic dilatation in Fbn1 
knockout mice (59).  A small study found angiotensin II receptor blockade slowed 
the rate of aortic-root dilatation in children with Marfan syndrome (61), which led to 
the initiation of several randomized control trials, many of which have yet to report 
their findings.  One study, COMPARE, has reported a beneficial effect of losartan 
in reducing aortic root dilatation in adults compared with placebo (62), although 
other studies have detected no benefit of losartan over β-blockade (63, 64).  In a 
recent head-to-head comparison, no significant differences in the progression 
ascending aorta dilatation between atenolol vs losartan treated groups over three 
years (65).  Interestingly, a sub-analysis of the COMPARE study suggested that 
the nature of the FBN1 mutation might dictate a patient’s response to angiotensin II 
receptor blockade (66).  Studies have not evaluated whether angiotensin II 
receptor blockade improves pneumothorax risk in patients with Marfan syndrome. 
Loeys-Dietz syndrome 
Loeys-Dietz syndrome was first described as a multisystem disorder caused by 
defects of TGFß receptor function leading to features including midline fusion 
defects (bifid uvula, hypertelorism, cleft palate), widespread arterial involvement 
with vascular tortuosity and high risk of aneurysms and dissection, along with and 
skeletal defects (scoliosis and elongation of the limbs)(67) (Figure 4).  Although the 
original description of this autosomal dominant condition did not include pulmonary 
features, considering the phenotypic similarities between Loeys-Dietz syndrome 
and Marfan syndrome, it is unsurprising that Loeys-Dietz syndrome has now been 
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linked with the development of spontaneous pneumothorax (68, 69).  In the 
American National Registry of Genetically Triggered Thoracic Aortic Aneurysms 
and Cardiovascular Conditions (GenTAC), 4 of 73 patients with Loeys-Dietz 
syndrome developed pneumothorax (70).  More recently, pneumothorax has been 
recognised as a presenting feature of the syndrome (69).   
There are currently five sub-types of Loeys-Dietz syndrome, classified by their 
mutations in components of the TGFß signalling pathway: TGFBR1, TGFBR2, 
SMAD3, TGFB2 and TGFB3 (71).  Paradoxically, loss-of-function mutations in 
these genes result in elevated TGFß signalling that, as with Marfan syndrome, may 
underlie the pathology of Loeys-Dietz Syndrome (72).  TGFß regulates many 
processes including angiogenesis and wound healing via cell surface receptors 
that signal both via a canonical pathway involving phosphorylation of SMAD 
transcription factors and via non-canonical SMAD-independent pathways.  
Dysregulation of TGFß signalling results in structural defects of the extracellular 
matrix perhaps due to an imbalance between deposition of the extracellular matrix, 
mediated by the canonical pathway, and matrix degradation, regulated by the non-
canonical pathway.  Components of the extracellular matrix can also feedback 
upon TGFß signalling because microfibrils within the matrix contain TGFß-binding 
proteins, such as fibrillin-1, that can sequester TGFß (73).  This could account for 
the increased TGFß-signalling seen when fibrillin-1 is lost in models of Marfan 
syndrome (59).  
Ehlers-Danlos syndrome 
Ehlers-Danlos syndrome (EDS) comprises a group of connective tissue disorders 
characterised by joint hypermobility, hyperextensible skin, easy bruising and 
dystrophic scarring, which are caused by mutations in a variety of genes (74).  
Most varieties of EDS have no recognised connection with lung disease, but 
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vascular EDS (vEDS, also known as EDS IV) is a rare cause of spontaneous 
pneumothorax.  Although vEDS is uncommon with a prevalence of less than 1 in 
100,000 (75), pneumothorax can precede other life-threatening complications by 
several years thus enabling recognition at an earlier stage.  The majority of 
patients with vEDS suffer a major complication such as spontaneous rupture of 
arteries (particularly middle sized arteries), intestines, or gravid uterus before the 
age of 40 years.   
vEDS is caused by autosomal dominant mutations in the COL3A1 gene, which 
encodes the collagen type III alpha 1 chain (76).  These mutations account for the 
phenotype because type III collagen is necessary for the integrity of both the 
pulmonary blood vasculature and the lung parenchyma (77).  Consequently, 
defects in COL3A1 predispose to pulmonary haemorrhage and the formation of 
parenchymal cysts or cavities (77-79).  Data from the GenTac Registry indicate 
that pneumothoraces occur in as many as 15% (16/107) of individuals with vEDS.  
Although the link between vEDS and spontaneous pneumothorax has been known 
for many years, low levels of clinical suspicion result in a majority of the published 
cases being diagnosed only following lung biopsy (79-84).  This is partially 
explained by the tendency of vEDS to resemble a pulmonary vasculitic process 
both clinically and on cross-sectional imaging, although autoimmune screens are 
typically negative (85).  
The shared pulmonary and vascular features of vEDS and other true connective 
tissue disorders suggest a degree of common pathology.  Indeed, individuals with 
vEDS have increased circulating levels of TGFβ1 and TGFβ2 and their dermal 
fibroblasts secrete more TGFβ2 than controls (86).  However, the effects of 
therapies targeting TGFβ signalling have yet to be studied in this condition.  The 
only human clinical trial to date in vEDS examined the effect of celiprolol, a mixed 
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β1-adrenoceptor antagonist and β2-adrenoceptor agonist (87).  This identified a 
moderate protective effect in reducing the occurrence of arterial rupture or 
dissection from 50% to 20%.   
α1-Antitrypsin deficiency 
Pneumothorax can complicate emphysema caused by excessive degradation of 
the extracellular matrix.  Since 1-2% of cases of COPD are due to α1-antitrypsin 
deficiency, pneumothorax can be the presenting feature of mutations in the 
SERPINA1 gene (98, 99).  While the benefits of replacement therapies remain 
debatable, early diagnosis permits beneficial lifestyle modification such as smoking 
cessation.  Many of the disease associated mutations cause polymerization of the 
protein within hepatocytes to cause liver dysfunction through effects on 
endoplasmic reticulum structure and luminal protein mobility (98, 100). Indeed, 
13% of patients homozygous for the Z allele die of liver disease.  Diagnosis 
therefore permits prospective monitoring for hepatic complications, which include 
cirrhosis and hepatocellular carcinoma. 
The rarest of the rare 
Homocystinuria and cutis laxa are rare even amongst true connective tissue 
disorders with estimated incidences of 1 per 4,000,000 and 1 per 60-100,000 
respectively (88, 89).  Homocystinuria is an autosomal recessive disorder caused 
by the deficiency of cystathionine-β-synthase, resulting in increased plasma levels 
of homocysteine and methionine.  Homocysteinylation of proteins, including 
fibrillin-1, manifests in many ways, for example osteoporosis, downwards 
subluxation of the lens, and neuropsychiatric disease.  Case studies suggest that 
pneumothoraces also occur (90, 91), but vascular events (thromboses and 
strokes) account for the majority of the condition’s morbidity, with half of patients 
affected before the age of 30 (92).  Although homocystinuria is screened for by the 
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neonatal heel prick test, a false negative rate of 0.03% means that diagnosis may 
not occur until complications present (93).  Also, patients may have been born prior 
to the introduction of routine testing for homocystinuria or in countries that still do 
not test.  Importantly, homocystinuria can be treated through dietary modification 
and so early diagnosis can yield large benefits (94).  Individuals with cutis laxa 
have abnormal elastic fibres that result in hypoelastic skin and sometimes in the 
development of emphysema.  Again, case reports suggest that spontaneous 
pnumothorax is also a manifestation of the disease (95, 96).  Mutations in several 
genes can cause cutis laxa, including ELN, FBLN4 and FBLN5, encoding elastin 
and fibrin proteins of the extracellular matrix. In mice, expression of a hypomorphic 
allele of Fbn4 was shown to cause aneurysm formation and to be associated with 
increased TGFβ signalling, suggesting that treatments developed for the more 
common true connective disease might prove useful for these patients (97). 
Concluding remarks 
Familial pneumothorax rather than being a single entity comprises a number of 
genetic disorders.  These can have severe extra-pulmonary manifestations ranging 
from renal cancer to aortic rupture.  Since pneumothorax is a common early 
presentation of these life-shortening diseases, it offers an important opportunity to 
make a diagnosis that can facilitate precision medicine.  Family tracing can 
subsequently identify many at-risk mutation carriers and so the health benefits are 
potentially wide reaching.  The diagnoses themselves are frequently 
straightforward when clinical context and radiology are considered, with genetic 
tests being confirmatory.  However, a high level of clinical suspicion is necessary if 
diagnoses are to be made and, above all, a family history must to be sought 
proactively. 
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Despite the large heritable component in spontaneous pneumothorax, up to half of 
cases remain unclassifiable following thorough investigation.  For this reason, 
familial pneumothorax has recently been added by Genomics England to the list of 
pulmonary disorders within the 100,000 Genomes Project [Rare Disease 
Conditions Eligibility Criteria v1.6.0 (2016) Genomics England].  The criteria for 
recruitment are (i) primary spontaneous pneumothorax, (ii) one or more affected 
relative, and (iii) prior testing for FLCN or FBN1 mutations if suggested by the 
clinical and radiological findings.  It is hoped that this systematic genome-wide 
analysis of familial pneumothorax will explain the aetiology of many of the 
remaining cases, be they formes frustes of known disorders or entirely new genetic 
entities.  Eventually, targeted gene panel testing will enter routine clinical practice 
for the investigation of pneumothorax. 
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Figure 1: Familial pneumothorax.  Familial pneumothorax accounts for 10% of 
all primary spontaneous pneumothoraces.  These can be further subdivided 
between those caused by mutations of tumour suppressors and those caused by 
defects of the extracellular matrix.  Approximately half of all familial 
pneumothoraces currently remain unclassifiable by standard clinical and genetic 
testing (unknown unknowns).  Abbreviations: Birt-Hogg-Dubé syndrome (BHD); 
Tuberous Sclerosis (TS); Lymphangioleiomyomatosis (LAM); Marfan syndrome 
(MFS); Loeys-Dietz syndrome (LDS); vascular Ehlers-Danlos syndrome (vEDS). 
Figure 2: Birt-Hogg-Dubé syndrome.  Coronal reconstruction of CT of a patient 
with Birt-Hogg-Dubé syndrome who had undergone previous left-sided 
pleurectomy.  Note the basal and medial preponderance of irregular cysts, some of 
which are multiseptated. Reproduced with permission from (101). 
Figure 3: Lymphangioleiomyomatosis.  Axial reconstruction of CT of a patient 
with lymphangioleiomyomatosis. Note multiple, bilateral thin walled cysts of varying 
size, some with a subpleural location. 
Figure 4: Loeys-Dietz syndrome. Photograph of bifid uvula characteristic of 
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